Avatrombopag, sold under the brand name Doptelet, is a medication that used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adults who are to undergo a planned medical or dental procedure.

[8][9] It was approved for medical use in the United States in May 2018,[10][11] the European Union in June 2019,[7] and Australia in January 2023.

[1] It acts as a thrombopoietin receptor agonist.

This drug article relating to the blood and blood forming organs is a stub.

You can help Wikipedia by expanding it.